MRK•benzinga•
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Summary
Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga